Biocon's Insulin Manufacturing Facility in Malaysia Completes USFDA inspection with three observations

Malaysia:Drug major Biocon recently informed about the USFDA inspection at its Insulin Manufacturing Facility in Malaysia, and that the agency issued a Form 483 with 3 observations which we believe are procedural in nature.

On February 22, 2020, Biocon's Insulin Manufacturing Facility in Malaysia Completes US FDA (PAI) Inspection.

The company informed that the U.S. Food and Drug Administration (FDA) conducted a pre-approval inspection (PAI) of our subsidiary, Biocon Sdn. Bhd's Insulins manufacturing facility based in Malaysia, for Insulin Glargine, between Feb 10 and Feb 21, 2020.

At the conclusion of the inspection, the agency issued a Form 483 with 3 observations which we believe are procedural in nature.

"We will respond to the FDA with an appropriate Corrective and Preventive Action Plan (CAPA) and are confident of addressing these observations expeditiously. The FDA has set a target action date for our Insulin Glargine application in June 2020. We believe the outcome of this inspection does not in any way impact the commercialization plans of insulin glargine in the US. Biocon Biologics is committed to global standards of Quality and Compliance." - said the Company Spokesperson,Mayank Verma, Company Secretary & Compliance Officer, Biocon.

Read also: USFDA issues Form 483 with 5 observations to Biocon Bengaluru facility

A copy of this has also been sent to BSE Limited and National Stock Exchange of India Limited.

Read also: Primary healthcare can play key role in combating outbreaks like coronavirus: Biocon Chief Kiran Mazumdar-Shaw